Early-stage biotech Identify INT as a development-stage biotechnology partner focused on tauopathies with an emphasis on disease-modifying approaches, presenting an opportunity for early collaboration, ad hoc consulting, or potential milestone-driven partnerships with larger pharma seeking a niche neurodegeneration pipeline.

Niche tauopathies Target the broad spectrum of tau-related neurodegenerative conditions (AD, FTD, CTE, PSP, CBD, FTDP-17, PDD) as a unified disease area, enabling a shared value proposition around tau biology, NFTs, and cognitive decline that may interest specialty CNS or biotech-focused funds and alliances.

Virtual operations Leverage INT’s virtual mode and lean team (0-1 employees) to offer cost-effective collaboration models, CRO-backed development plans, and flexible engagement terms appealing to partners seeking efficient, capital-light exploration or co-development arrangements.

Founder-led roadmap Capitalize on leadership continuity with founder CEO Shawn Mojtahedian to position strategic discussions around IP, platform readiness, and grant or non-dilutive funding opportunities, while aligning with potential buyers or investors valuing founder-led insight.

Funding and visibility gaps Note revenue under one million and frequent conference activity, suggesting a market opportunity to connect with investors and strategic acquirers at CNS/biotech events, and to present a compelling value case for accelerating preclinical or translational milestones to de-risk an eventual partnership or acquisition.